- Home
- ZNTL vs ARMP Comparison
ZNTL vs ARMP Comparison
Compare ZNTL & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- ARMP
- Stock Information
- Founded
- ZNTL 2014
- ARMP N/A
- Country
- ZNTL United States
- ARMP United States
- Employees
- ZNTL N/A
- ARMP N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZNTL Health Care
- ARMP Health Care
- Exchange
- ZNTL Nasdaq
- ARMP Nasdaq
- Market Cap
- ZNTL 105.8M
- ARMP 92.4M
- IPO Year
- ZNTL 2020
- ARMP N/A
- Fundamental
- Price
- ZNTL $1.99
- ARMP $2.61
- Analyst Decision
- ZNTL Buy
- ARMP Strong Buy
- Analyst Count
- ZNTL 7
- ARMP 1
- Target Price
- ZNTL $8.46
- ARMP $9.00
- AVG Volume (30 Days)
- ZNTL 784.9K
- ARMP 9.8K
- Earning Date
- ZNTL 08-06-2025
- ARMP 08-12-2025
- Dividend Yield
- ZNTL N/A
- ARMP N/A
- EPS Growth
- ZNTL N/A
- ARMP N/A
- EPS
- ZNTL N/A
- ARMP N/A
- Revenue
- ZNTL $26,865,000.00
- ARMP $6,868,000.00
- Revenue This Year
- ZNTL N/A
- ARMP $8.43
- Revenue Next Year
- ZNTL N/A
- ARMP N/A
- P/E Ratio
- ZNTL N/A
- ARMP N/A
- Revenue Growth
- ZNTL N/A
- ARMP 84.67
- 52 Week Low
- ZNTL $1.01
- ARMP $0.90
- 52 Week High
- ZNTL $5.44
- ARMP $2.96
- Technical
- Relative Strength Index (RSI)
- ZNTL 78.59
- ARMP 58.67
- Support Level
- ZNTL $1.55
- ARMP $2.43
- Resistance Level
- ZNTL $1.70
- ARMP $2.72
- Average True Range (ATR)
- ZNTL 0.12
- ARMP 0.18
- MACD
- ZNTL 0.05
- ARMP -0.01
- Stochastic Oscillator
- ZNTL 91.43
- ARMP 70.08
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.